Christopher J. Scoggins - 12 Dec 2025 Form 3 Insider Report for ABBOTT LABORATORIES (ABT)

Role: EXECUTIVE VICE PRESIDENT
Signature: /s/ Christopher J. Scoggins by Jessica H. Paik, Attorney-in-Fact
Issuer symbol: ABT
Transactions as of: 12 Dec 2025
Net transactions value: $0
Form type: 3
Filing time: 19 Dec 2025, 16:39:46 UTC
Next filing: 26 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Scoggins Christopher J	EXECUTIVE VICE PRESIDENT	100 ABBOTT PARK ROAD, ABBOTT PARK	/s/ Christopher J. Scoggins by Jessica H. Paik, Attorney-in-Fact	19 Dec 2025	0001772286

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ABT	Common shares without par value						63,621	12 Dec 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ABT	Option (right to buy)							12 Dec 2025	Common shares	51,557	$75.90	Direct	F1
holding	ABT	Option (right to buy)							12 Dec 2025	Common shares	43,388	$79.98	Direct	F1
holding	ABT	Option (right to buy)							12 Dec 2025	Common shares	68,578	$87.72	Direct	F1
holding	ABT	Option (right to buy)							12 Dec 2025	Common shares	63,991	$124.04	Direct	F1
holding	ABT	Option (right to buy)							12 Dec 2025	Common shares	48,852	$117.58	Direct	F1
holding	ABT	Option (right to buy)							12 Dec 2025	Common shares	37,483	$106.24	Direct	F2
holding	ABT	Option (right to buy)							12 Dec 2025	Common shares	31,721	$116.98	Direct	F3
holding	ABT	Option (right to buy)							12 Dec 2025	Common shares	45,730	$135.42	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
F2	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,494 on February 17, 2024, 12,494 on February 17, 2025, and 12,495 on February 17, 2026.
F3	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,573 on February 21, 2025, 10,574 on February 21, 2026, and 10,574 on February 21, 2027.
F4	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,243 on February 25, 2026, 15,243 on February 25, 2027, and 15,244 on February 25, 2028.